Short answer
Probably a little, mainly with falling asleep, but the proof is thin. A 2021 meta-analysis pooled 9 small randomized trials with 388 participants. Oral micronized progesterone shortened the time it took to fall asleep but did not clearly improve total sleep time or sleep efficiency. Drowsiness is a listed side effect. Sleep is not an FDA-approved use.
What the pooled trials show
The best summary is a systematic review in the Journal of Clinical Endocrinology and Metabolism (2021). It found 9 randomized controlled trials with 388 participants. Eight of the trials enrolled postmenopausal women.
A meta-analysis of 4 of those trials favored micronized progesterone for sleep onset latency, the time it takes to fall asleep. It did not show a clear gain in total sleep time or sleep efficiency. Self-reported sleep improved in most trials. The authors called the studies inconsistent, and said estradiol taken at the same time and fewer hot flashes limit the conclusions.
How small the key trials are
A 2008 crossover trial gave 300 mg of oral micronized progesterone for 21 days to 10 healthy postmenopausal women aged 54 to 70. Time spent awake during the night went down, and daytime thinking tests did not change.
A 2011 trial studied eight healthy postmenopausal women with no sleep complaints, taking 300 mg at 11 pm for three weeks. Progesterone had no effect on undisturbed sleep. On a night disturbed by blood sampling, time awake after falling asleep was 53% lower than on placebo. Ten and eight women are not enough to settle the question.
What the FDA label says
The Prometrium label lists two approved uses: preventing endometrial hyperplasia in postmenopausal women with a uterus who take conjugated estrogens, and secondary amenorrhea. Sleep is not one of them.
The label does say the capsules may cause transient dizziness and drowsiness, and that they should be taken as a single daily dose at bedtime. The patient leaflet says some women become very drowsy or dizzy after a dose. The Menopause Society's 2022 position statement describes oral micronized progesterone as mildly sedating and says it should be given at night.
What that means for your decision
A drowsy side effect is not the same as a proven insomnia treatment. The two trials described above lasted three weeks each, and most of the evidence comes from women after menopause. The trials covered here did not compare oral progesterone with other ways of protecting the uterine lining for sleep.
If sleep is part of why you value your current prescription, say so to your prescriber. Which progestogen you use, and in what form, is a decision to make together. Do not stop or swap it on your own.
Related questions
Is progesterone FDA-approved as a sleep aid?
No. The Prometrium label lists prevention of endometrial hyperplasia in women taking conjugated estrogens, and secondary amenorrhea. Drowsiness appears in the label as a precaution, not as a benefit.
Why does the label say to take it at bedtime?
The label says the capsules may cause transient dizziness and drowsiness, and tells you to use caution when driving or operating machinery. Bedtime dosing is how the label handles that.
Did the trials test perimenopausal women?
Mostly not. Eight of the nine trials in the 2021 review enrolled postmenopausal women, so the findings may not carry over to perimenopause.
Read next
Sources
- Nolan et al., J Clin Endocrinol Metab: Efficacy of Micronized Progesterone for Sleep, systematic review and meta-analysis (2021)
- Schüssler et al., Psychoneuroendocrinology: Progesterone reduces wakefulness in sleep EEG in healthy postmenopausal women (2008)
- Caufriez et al., J Clin Endocrinol Metab: Progesterone prevents sleep disturbances in postmenopausal women (2011)
- DailyMed (NIH): Prometrium (progesterone) capsule prescribing information (label version published 27 Jul 2026)
- The Menopause Society: The 2022 Hormone Therapy Position Statement of The North American Menopause Society (2022)
Published 2026-10-04 · Last checked 2026-10-04
Educational content, not medical advice. Made for the United States.